Sanofi SA to Stop Clinical Trials of Fedratinib JAK2 Inhibitor


Monday, 18 Nov 2013 01:00am EST 

Sanofi SA announced that it has decided to stop all clinical trials of its experimental agent fedratinib (SAR302503), a JAK2 inhibitor, and to annulate its projects of filing for homologation to regulatory bodies. As a result of a thorough risk-benefit analysis and consultations with the U.S. Food and Drug Administration, clinical trials investigators and independent neurology and neuroradiology experts, the Company estimated, that the risk of fedratinib having negative impact on patients outweigh the potential benefits. 

Company Quote

74.99
-0.65 -0.86%
24 Dec 2014